Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | HTR2B | P41595 | 3/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13849354 | 1.00 | SYK (0.64) | SYKPOLBALDH1A1NPC1HTR2C | |
| SCHEMBL14420826 | 0.85 | POLB (0.67) | SYKPOLBALDH1A1NPC1TSHR | |
| SCHEMBL4088385 | 0.84 | SYK (0.59) | SYKPOLBHTR2CHTR2BHTR2A | |
| SCHEMBL12781713 | 0.82 | SYK (0.56) | SYKPOLBHTR2CHTR2BHTR2A | |
| SCHEMBL12409038 | 0.82 | SYK (0.71) | SYKPOLBALDH1A1NPC1HTR2C | |
| SCHEMBL13963827 | 0.82 | SYK (0.71) | SYKPOLBALDH1A1NPC1HTR2C | |
| SCHEMBL12311750 | 0.81 | NPC1 (0.70) | SYKPOLBALDH1A1NPC1HTR2B | |
| SCHEMBL1911850 | 0.81 | NPC1 (0.66) | SYKPOLBALDH1A1NPC1HTR2B | |
| SCHEMBL14399504 | 0.79 | SYK (0.53) | SYKPOLBALDH1A1HTR2CHTR2B | |
| SCHEMBL4106609 | 0.79 | CHEK1 (0.60) | SYKPOLBALDH1A1NPC1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K5 | SYK 782/4885POLB 2085/4885ALDH1A1 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.